Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Docetaxel/ritonavir - Modra Pharmaceuticals

Next Previous
X
Search
Drug Profile

Docetaxel/ritonavir - Modra Pharmaceuticals

Alternative Names: Docetaxel plus ritonavir - Modra Pharmaceuticals; ModraDoc 006; ModraDoc 006/r; ModraDoc001; ModraDoc003; Oral docetaxel formulation - Modra Pharmaceuticals

Latest Information Update: 28 Jul 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Modra Pharmaceuticals
  • Developer Modra Pharmaceuticals; Netherlands Cancer Institute
  • Class Amides; Antineoplastics; Carbamates; Small molecules; Taxanes; Thiazoles
  • Mechanism of Action Cytochrome P-450 enzyme system inhibitors; Mitosis inhibitors; P-glycoprotein inhibitors; Tubulin inhibitors; Tubulin polymerisation promoters
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Breast cancer; Prostate cancer; Solid tumours

Most Recent Events

  • 28 Jul 2024 No recent reports of development identified for phase-I development in Prostate-cancer(Combination therapy, Early-stage disease, Hormone refractory) in Netherlands (PO, Tablet)
  • 16 Mar 2023 Modra Pharmaceuticals announces US patent issuance for docetaxel/ritonavir
  • 11 Jul 2022 Docetaxel/ritonavir is still in phase I trials for Prostate cancer (Combination therapy, Early-stage disease, Hormone refractory) in Netherlands (Modra Pharmaceuticals pipeline, July 2022)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top